dihexa hgf c met synaptogenesis 20mg Qty25 – NewBioRx Frontiers | HGF and MET:

Appetite Suppression Studies: Potently reduces food intake in preclinical models

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy

While these lines of evidence support the role of the stomach as the site of FPM, it should be noted that the elimination of FPM by gastrectomy and its modulation by food or drugs that alter gastric emptying does not conclusively prove that the liver is not the main site for FPM

CagriSema showed 22.7% at 68 weeks, but Novo Nordisk is running a direct head-to-head trial (NCT06131437) that will settle the comparison in a way indirect data cannot